Cambridge Trust’s Hologic HOLX Stock Holding History

Cambridge Trust’s Portfolio HOLX Stock Details HOLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-161	Closed	-$12K	–	898
2022 Q1	$12K	Sell	161 -4	-2%	-$288	﹤0.01%	729
2021 Q4	$13K	Buy	+165	New	+$12.1K	﹤0.01%	768

Other funds holding HOLX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Cambridge Trust's HOLX Position: Q2 2022 in Review

Cambridge Trust sold out of Hologic (HOLX) in Q2 2022, closing a stake of 161 shares — an estimated $12K sold.

Cambridge Trust first reported a position in HOLX in Q4 2021 and held it in 2 quarters. The position peaked at $13K in Q4 2021. 695 funds tracked by Wall St. Rank hold HOLX as of Q2 2022.

Cambridge Trust reported no remaining Hologic position as of Q2 2022 after selling out during the quarter.
Cambridge Trust sold 161 Hologic shares in Q2 2022, an estimated $12K.
Cambridge Trust first reported a position in Hologic in Q4 2021 and held it in 2 quarters.
Cambridge Trust's Hologic position peaked at $13K in Q4 2021.
695 funds tracked by Wall St. Rank held Hologic as of Q2 2022.

Based on Cambridge Trust's 13F filing for Q2 2022, filed 16 Aug 2022.